The telehealth sector pioneer Hims & Hers has sent shockwaves through the investment community with its latest quarterly earnings report, triggering a dramatic sell-off that erased nearly half the stock’s value from its yearly peak. Shares collapsed from almost $73 to approximately $41, creating a puzzling scenario where explosive customer growth coincides with investor panic.
Profitability Concerns Overshadow Revenue Gains
Third-quarter financial results reveal a complex picture. While revenue surged an impressive 49% to reach $599 million, comfortably exceeding analyst projections, underlying issues emerged. The company’s customer base expanded significantly to nearly 2.5 million users, representing a 21% year-over-year increase.
However, these positive indicators were undermined by troubling financial metrics. Gross margins contracted substantially from 79% to 74%, while net income experienced a dramatic fall from $75.6 million during the same period last year to just $15.8 million. Earnings per share missed expectations by a staggering 40%, raising fundamental questions about whether Hims & Hers can achieve sustainable, profitable expansion.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Strategic Partnerships and Divergent Analyst Views
Market attention has turned to potential strategic moves that could revitalize the company’s prospects. Hims & Hers confirmed it is engaged in active discussions with Danish pharmaceutical giant Novo Nordisk regarding a potential collaboration in the weight-loss medication sector. The hugely popular GLP-1 drugs represent a multi-billion dollar market opportunity that could provide substantial momentum.
Financial experts remain deeply divided on the company’s outlook. Bank of America Securities has issued a cautious warning with a price target of just $32, suggesting further potential declines. In stark contrast, BTIG maintains an optimistic $85 valuation—more than double the current trading level. The recent acquisition of ZAVA, facilitating European market entry, may deliver medium-term relief, though near-term pressures continue to mount.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from November 11 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 11.
Hims & Hers: Buy or sell? Read more here...
